Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index; 18 of the 36 sources its claims cite were checked for support.

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition

Open access

Published version of a preprint

Abstract

The gut microbiota is considered a key player modulating the efficacy of immune checkpoint inhibitor therapy. The study investigated the association between the response to anti-PD-1 therapy and the baseline gut microbiome in a Polish cohort of melanoma patients, alongside selected agents modifying the microbiome. Sixty-four melanoma patients enrolled for the anti-PD-1 therapy, and ten healthy subjects were recruited. The response to the treatment was assessed according to the response evaluation criteria in solid tumors, and patients were classified as responders or non-responders. The association between selected extrinsic factors and response was investigated using questionnaire-based analysis and the metataxonomics of the microbiota. In the responders, the Bacteroidota to Firmicutes ratio was higher, and the richness was decreased. The abundance of Prevotella copri and Bacteroides uniformis was related to the response, whereas the non-responders’ gut microbiota was enriched with Faecalibacterium prausnitzii and Desulfovibrio intestinalis and some unclassified Firmicutes. Dietary patterns, including plant, dairy, and fat consumption as well as gastrointestinal tract functioning were significantly associated with the therapeutic effects of the therapy. The specific gut microbiota along with diet were found to be associated with the response to the therapy in the population of melanoma patients.

Overview

CoChat Summary

TL;DR

In a Polish cohort of 64 melanoma patients and 10 healthy controls, baseline gut microbiome composition was associated with anti-PD-1 response: responders had a higher Bacteroidota/Firmicutes ratio, lower richness, and enrichment of *Prevotella copri* and *Bacteroides uniformis*, while non-responders were enriched with *Faecalibacterium prausnitzii* and *Desulfovibrio intestinalis*. Diet and gastrointestinal factors, including high plant consumption, low dairy consumption, and daily defecation, were also associated with therapeutic response.

Key findings

  • Among 25 responders, 32 non-responders, and 10 controls, the median Bacteroidota to Firmicutes ratio was higher in responders (0.51) than controls (0.44) and non-responders (0.42), with a significant R–NR difference (p < 0.05). Responders also had significantly lower microbial richness than non-responders (p < 0.05), and baseline beta diversity differed between R and NR (R² = 0.0357, p = 0.0033).
  • Response was associated with enrichment of ASVs belonging to *Prevotella copri* and *Bacteroides uniformis*; non-responders were enriched with *Faecalibacterium prausnitzii*, *Desulfovibrio intestinalis*, and unclassified Firmicutes (orders Izemoplasmatales and Clostridia UCG-014, family Oscillospiraceae).
  • Questionnaire analysis found high plant consumption associated with a 2.9-fold increase in probability of response, and low dairy consumption (≤1 portion/day) with a 2.0-fold increase. Mixed dietary fat consumption was declared by 36.0% of responders vs 6.9% of non-responders; daily defecation by 62.5% of responders vs 43.3% of non-responders, while defecating every second day was reported by 4.2% of responders vs 40.0% of non-responders.
  • Median stool calprotectin was 32.75, 54.69, and 76.99 µg/mL for controls, responders, and non-responders, respectively, but differences were not statistically significant (p > 0.05). Elevated serum LDH (>250 U/L) occurred in 21% of responders and 42% of non-responders, and median LDH was significantly higher in non-responders (p < 0.05).

Methods

  • Prospective cohort recruited at Poznan University of Medical Sciences from June 2018 to December 2021: 64 patients with unresectable stage III or IV cutaneous melanoma starting anti-PD-1 therapy (nivolumab or pembrolizumab), plus 10 healthy relatives as controls. Response was assessed by RECIST v1.1: responders = CR/PR, non-responders = SD/PD; clinical benefit = CR/PR/SD, no benefit = PD.
  • Baseline questionnaires (39 closed questions) covered socio-demographic, anthropometric, clinical, lifestyle, and dietary variables; stool samples were collected before treatment. Fecal calprotectin was measured by ELISA; microbiota was analyzed by 16S rRNA V3–V4 sequencing on Illumina MiSeq PE300, with selected samples also subjected to shotgun metagenomics on Illumina NovaSeq 6000 PE150 (n = 16).
  • Analyses included Kruskal–Wallis and Fisher’s exact tests, relative risk for questionnaire variables, DADA2/SILVA taxonomy, alpha/beta diversity in R, PERMANOVA, and limma for differential taxa; metagenomic assembly and binning reconstructed metagenome-assembled genomes.

Limitations

  • The paper states that the control group was small and significantly younger than patients, and that patients and controls differed significantly in birthplace, plant portion consumption, and defecation frequency; these factors were considered in microbiota analysis.
  • The paper states that dietary fat findings could not identify which specific fat type or products were associated with improved outcomes, and that further studies with larger sample sizes and more specified extrinsic factors are needed.
  • Evident from the text: this is a single-country cohort with a modest sample size, shotgun metagenomics was performed on only 16 selected samples, and the reported associations are baseline/cross-sectional and do not establish causality.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers14215369

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The gut microbiota composition (relative abundance) of the study cohort at the phylum level. Analyzed samples were grouped into C—controls, R—responders, and NR—non-responders.
Figure 1 The gut microbiota composition (relative abundance) of the study cohort at the phylum level. Analyzed samples were grouped into C—controls, R—responders, and NR—non-responders.CC BY · PubMed Central
Figure 2 Bacteroidota/Firmicutes ratio differs significantly (p < 0.05, t-test) for the responder (R) and non-responder (NR) groups.
Figure 2 Bacteroidota/Firmicutes ratio differs significantly (p < 0.05, t-test) for the responder (R) and non-responder (NR) groups.CC BY · PubMed Central
Figure 3 The inflammatory state of gut mucosa was evaluated by calprotectin concentration measurement in the stool of study participants. Comparison between groups of controls (C) and the anti-PD-1 recipients before the first injection of the ICI therapeutics, classified as responders (R) and non-responders (NR) according to the clinical outcome of ICI therapy. The p-values describing the statistical significance of the calprotectin level in the study groups were calculated with Wilcoxon Rank Sum Test. The plot is in a logarithmic scale.
Figure 3 The inflammatory state of gut mucosa was evaluated by calprotectin concentration measurement in the stool of study participants. Comparison between groups of controls (C) and the anti-PD-1 recipients before the first injection of the ICI therapeutics, classified as responders (R) and non-responders (NR) according to the clinical outcome of ICI therapy. The p-values describing the statistical significance of the calprotectin level in the study groups were calculated with Wilcoxon Rank Sum Test. The plot is in a logarithmic scale.CC BY · PubMed Central
Figure 4 Plots depicting a comparison of bacterial ASV alpha diversity of the stool microbiota as estimated regarding richness (ACE, Chao1, and observed indices), evenness (Pielou index), and diversity (Shannon and Simpson indices) measures in study groups (R—responders, NR—non-responders, and C—controls). Wilcoxon Rank Sum Test indicated that the responder and non-responder groups’ microbiota differed in regards to richness (p < 0.05).
Figure 4 Plots depicting a comparison of bacterial ASV alpha diversity of the stool microbiota as estimated regarding richness (ACE, Chao1, and observed indices), evenness (Pielou index), and diversity (Shannon and Simpson indices) measures in study groups (R—responders, NR—non-responders, and C—controls). Wilcoxon Rank Sum Test indicated that the responder and non-responder groups’ microbiota differed in regards to richness (p < 0.05).CC BY · PubMed Central
Figure 5 NMDS (non-metric multidimensional scaling) plot based on Bray–Curtis dissimilarity of the bacterial microbiota composition in study groups (R—responders, NR—non-responders, and C—controls). Permutation multivariate analysis of variance revealed significant differences between the groups (R2 = 0.0491 and p = 0.0089).
Figure 5 NMDS (non-metric multidimensional scaling) plot based on Bray–Curtis dissimilarity of the bacterial microbiota composition in study groups (R—responders, NR—non-responders, and C—controls). Permutation multivariate analysis of variance revealed significant differences between the groups (R2 = 0.0491 and p = 0.0089).CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 0 Not valid · 13 Not checked · 48 Own results and interpretations

26 more claims

Create a free account to see all 74 claims and to verify the 18 references still open.

See all claims — free account
  • Probably not a substantial claim. 34
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 83 references

Research works printed but not linked: 2

  1. Szmulski, 2019, Obwieszczenie Nr 65 Ministra Zdrowia z Dnia 30 Sierpnia 2019 r. w Sprawie Wykazu Refundowanych Leków, Środków Spożywczych Specjalnego Przeznaczenia Żywieniowego Oraz Wyrobów Medycznych, Off. J. Minist. Health-Pol., 65, 906
  2. Dziedzic, 2011, Poród domowy w opinii położnych, Probl. Pielęgniarstwa, 19, 153

Cited by

See all 36

Metadata

Authors
Pietrzak, B., Tomela, K., Olejnik-Schmidt, A., Galus, Ł., Mackiewicz, J., Kaczmarek, M., Mackiewicz, A., & Schmidt, M.
Affiliations
  • Poznań University of Life Sciences (PL)
  • Poznan University of Medical Sciences (PL)
  • Department of Biotechnology and Food Microbiology, Poznan University of Life Sciences, 60-627 Poznan, Poland
Corresponding author
  • Pietrzak, Bernadeta
  • Schmidt, Marcin
Venue
Cancers
Publisher
MDPI AG
Published
2022-10-31
Volume
14
Issue
21
Pages
5369
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4308126031
Cited by
36
References
83
Citations by year
2026: 12 · 2025: 10 · 2024: 11 · 2023: 2 · 2022: 1
FWCI
1.96
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Science Centre, Poland (2017/25/B/NZ5/01949)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, gut microbiota, treatment response, Prevotella copri, Bacteroides uniformis, Faecalibacterium prausnitzii, dietary habits, gastrointestinal function, Polish patients

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition. https://app.cochat.ai/papers/10.3390/cancers14215369
The paper
Pietrzak, B., Tomela, K., Olejnik-Schmidt, A., Galus, Ł., Mackiewicz, J., Kaczmarek, M., Mackiewicz, A., & Schmidt, M. (2022). A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition. Cancers. https://doi.org/10.3390/cancers14215369

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.